
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's operational sales growth reached 11.5% in the fourth quarter of 2025, despite a significant headwind from generic competition for Stelara, highlighting the strength of the company's innovative medicine and medtech divisions following the divestiture of its consumer business. The company's revised revenue and earnings projections for 2026 indicate an expected total revenue of $100.42 billion and earnings per share of $11.52, driven by strong performance in products such as Rybrevant and Tremfya. With the stock demonstrating a robust performance increase of approximately 30% since July 1, 2025, and favorable adjustments to earnings estimates, a positive outlook for Johnson & Johnson's stock persists.
Bears say
Johnson & Johnson faces significant risks that could negatively impact its financial outlook, including potential rapid sales declines from the loss of patent exclusivity and unfavorable launches or data readouts for key pipeline products. Additionally, increasing investor apprehension surrounding macroeconomic issues, such as U.S. drug pricing reform and ongoing litigation related to product liability, could further contribute to volatility in JNJ's stock performance. The combination of these factors suggests a challenging environment that may restrain revenue growth and profitability for the healthcare giant.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares